Simulation Modeling of coronary ARTery disease: a tool for clinical decision support

Acronym

SMARTool

Description of the granted funding

SMARTool aims at developing a platform based on cloud technology, for the management of patients with coronary artery disease (CAD) by standardizing and integrating heterogeneous health data, including those from key enabling technologies. The platform includes existing multiscale and multilevel ARTreat (FP7-224297) models of coronary plaque progression based on non-invasive coronary CT angiography (CCTA) and fractional flow reserve computation, refined by heterogeneous patient-specific non-imaging data (history, lifestyle, exposome, biohumoral data, genotyping) and cellular/molecular markers derivable from a microfluidic device for on-chip blood analysis. SMARTool models will be applied and validated by historical and newly acquired CCTA imaging plus non-imaging health data from the EVINCI project (FP7-222915) population. SMARTool cloud-based platform, through Human Computer Interaction techniques, 3D visual representation and artery models, will use heterogeneous data in a standardized format as input, providing as output a CDSS - assisted by a microfluidic device as a point of care testing of inflammatory markers – for: i) Patient specific CAD stratification - existing models, based on clinical risk factors, will be implemented by patient genotyping and phenotyping to stratify patients with non-obstructive CAD, obstructive CAD and those without CAD, ii) site specific plaque progression prediction - existing multiscale and multilevel ARTreat tools of CAD progression prediction will be refined by genotyping and phenotyping parameters and tested by baseline and follow CCTA and integrated by non-imaging patient-specific data, iii) patient-specific CAD diagnosis and treatment - life style changes, standard or high intensity medical therapy and a virtual angioplasty tool to provide the optimal stent type(s) and site(s) for appropriate deployment.
Show more

Starting year

2016

End year

2019

Granted funding

110 422.5 €
Participant
97 651.25 €
Third party
UNIVERSITAT ZURICH (CH)
Participant
FAKULTET INZENJERSKIH NAUKA UNIVERZITETA U KRAGUJEVCU (RS)
319 500 €
Participant
BIOTRONICS 3D LIMITED (UK)
331 375 €
Participant
ALACRIS THERANOSTICS GMBH (DE)
811 375 €
Participant
MICRONIT MICROTECHNOLOGIES BV (NL)
372 695 €
Participant
EXPRIVIA SPA (IT)
318 952.5 €
Participant
FONDAZIONE TOSCANA GABRIELE MONASTERIO PER LA RICERCA MEDICA E DI SANITA PUBBLICA (IT)
343 476.25 €
Participant
UNIVERSITAT ZURICH (CH)
Participant
CONSIGLIO NAZIONALE DELLE RICERCHE (IT)
1 200 411.25 €
Coordinator
ACADEMISCH ZIEKENHUIS LEIDEN (NL)
220 000 €
Participant
IDRYMA TECHNOLOGIAS KAI EREVNAS (EL)
675 000 €
Participant

Amount granted

4 800 859 €

Funder

European Union

Funding instrument

Research and Innovation action

Framework programme

Horizon 2020 Framework Programme

Call

Programme part
Health (5290)
Methods and data (5305)
Topic
Digital representation of health data to improve disease diagnosis and treatment (PHC-30-2015)
Call ID
H2020-PHC-2015-single-stage

Other information

Funding decision number

689068

Identified topics

cardiovascular diseases